Omeros

Omeros PEG

The PEG Ratio (Price/Earnings-to-Growth) of Omeros (OMER) as of Oct 11, 2026 is -3.85.

PEG

-3.85

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Omeros is 2025 -3.85 . PEG Ratio (Price/Earnings-to-Growth) of Omeros was 2024 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Omeros Stock analysis

What does Omeros do? Omeros Corp is a biopharmaceutical company based in Seattle, Washington, that focuses on the discovery, development, and commercialization of innovative therapies. The company has developed a wide range of products and technologies in various areas of the medical sector, including ophthalmology, immunology, oncology, and neurology. Omeros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Omeros stock

PEG Ratio (Price/Earnings-to-Growth) of Omeros is -3.85 in 2025.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Omeros since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Omeros with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Omeros

All Key Metrics — Omeros